 ENGLEWOOD, Colo., May 10, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board IRB approval to commence enrollment in its AP-018 Phase I study using inhaled AmpionTM with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long or long-haul COVID, or Post-Acute Sequelae of SARS-CoV-2. 